Functional Mechanisms and Therapeutic Approaches for the Regulation of m6A Modification in Glioblastoma

Simon Walker^*
*Correspondence: Simon Walker, Department of Brain Tumour Research Centre, University of Nottingham, Nottingham NG7 2RD, UK, Email:

Introduction

Glioblastoma (GBM) is one of the most aggressive and lethal types of brain tumors. Despite considerable advances in cancer research, the treatment options for GBM remain limited, and the survival rate remains poor. In recent years, epigenetic modifications, such as N6-methyladenosine (m6A) RNA methylation, have emerged as critical players in the development and progression of GBM. This article explores the functional mechanisms of m6A modification in GBM and highlights potential therapeutic approaches aimed at targeting this epigenetic modification to improve patient outcomes. Glioblastoma is a grade IV astrocytoma characterized by its high proliferation, invasion, and angiogenesis. The standard treatment, consisting of surgery, radiation, and chemotherapy, offers only limited improvement in overall survival [1]. As the demand for novel therapeutic targets increases, epigenetic modifications have gained attention for their significant role in cancer pathogenesis. Among these modifications, m6A RNA methylation has emerged as a prominent regulator of gene expression, warranting investigation into its functional mechanisms and therapeutic potential in GBM. m6A is the most abundant internal RNA modification, affecting mRNA stability, splicing, and translation efficiency. Multiple studies have reported aberrant m6A modification patterns in GBM, suggesting its involvement in gliomagenesis. METTL3, the primary writer, is upregulated in GBM and correlates with poor prognosis. The increased expression of METTL3 enhances m6A levels in key oncogenic transcripts, promoting their stability and translation.

Description

Conversely, FTO, a key demethylase, has been shown to be downregulated in GBM, contributing to elevated m6A levels and stabilizing transcripts that drive cancer progression. Dysregulated m6A modification in GBM can modulate critical pathways, including the PI3K/AKT and Wnt/β-catenin pathways, promoting tumor growth and invasion. The dysregulated m6A landscape in GBM affects multiple aspects of tumor biology. Increased m6A modification in certain transcripts, such as EGFR and MYC, enhances their stability and expression, leading to the activation of signaling pathways that drive cell proliferation and survival. Additionally, m6A modification can regulate alternative splicing events, altering the isoform expression of key genes involved in cancer progression. Furthermore, m6A modification impacts the tumor microenvironment, influencing interactions between cancer cells and surrounding stromal cells, such as tumorassociated macrophages and endothelial cells. Developing small molecule inhibitors targeting m6A writers (e.g., METTL3) or promoting m6A erasers (e.g., FTO) could restore the balance of m6A modification, leading to the degradation of oncogenic transcripts and tumor suppression [2].

Targeting m6A-binding proteins, such as YTHDF and YTHDC, could interfere with their interaction with m6A-modified transcripts, affecting the stability and translation of oncogenes. Combining m6A-targeting therapies with existing treatment modalities, such as chemotherapy or immunotherapy, may yield synergistic effects and improve therapeutic outcomes. RNA-based approaches, such as m6A-modified antisense oligonucleotides, could be employed to specifically target and degrade oncogenic transcripts with increased m6A levels [3]. Despite the promising potential of targeting m6A in GBM, several challenges need to be addressed, including off-target effects, delivery methods, and potential resistance mechanisms. Nevertheless, with ongoing advancements in epigenetic research and drug development, therapeutic approaches targeting m6A could revolutionize GBM treatment and significantly improve patient survival [4].

Several functional mechanisms by which dysregulated m6A modification contributes to GBM pathogenesis have been identified. Firstly, m6A modification influences the stability and translation efficiency of mRNA transcripts, thereby affecting the expression of critical oncogenes and tumor suppressors. Secondly, m6A modification regulates alternative splicing events, leading to transcript isoform switching and altered protein functionality. Additionally, m6A modification influences RNA secondary structure, RNA-protein interactions, and long noncoding RNA functions, further impacting GBM development and progression. Dysregulation of m6A modification has been implicated in various cancer types, including GBM, and has emerged as a potential therapeutic target. Understanding the functional mechanisms of m6A modification in GBM and developing therapeutic approaches to regulate m6A levels hold promise for improving patient outcomes [5].

Conclusion

Epigenetic modifications, including m6A RNA methylation, play a pivotal role in the development and progression of GBM. Understanding the functional mechanisms of m6A dysregulation provides valuable insights into potential therapeutic targets. Targeting m6A writers, erasers, and readers holds promise for novel GBM therapies, which may complement existing treatment strategies and ultimately improve patient outcomes. As research in this field continues, the development of m6A-targeted therapies may bring us closer to effectively combatting this devastating brain tumor. m6A modification represents a promising avenue for therapeutic intervention in GBM. Targeting dysregulated m6A modification holds the potential to restore normal gene regulation and improve patient outcomes. Continued research efforts in this field are crucial to uncover the full therapeutic potential of m6A modulation in GBM treatment. Several functional mechanisms by which dysregulated m6A modification contributes to GBM pathogenesis have been identified. Firstly, m6A modification influences the stability and translation efficiency of mRNA transcripts, thereby affecting the expression of critical oncogenes and tumor suppressors. Secondly, m6A modification regulates alternative splicing events, leading to transcript isoform switching and altered protein functionality. Additionally, m6A modification influences RNA secondary structure, RNA-protein interactions, and long noncoding RNA functions, further impacting GBM development and progression. Targeting dysregulated m6A modification presents a promising avenue for therapeutic intervention in GBM. Several approaches have been explored to restore proper m6A levels and functions in GBM cells. These strategies mainly focus on the modulation of m6A writers, erasers and readers.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Boulias, Konstantinos and Eric Lieberman Greer. "Biological roles of adenine methylation in RNA." Nat Rev Genet 24 (2023): 143-160.

Google Scholar, Crossref, Indexed at

2. Dominissini, Dan, Sharon Moshitch-Moshkovitz, Schraga Schwartz and Mali Salmon-Divon, et al. "Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq." Nature 485 (2012): 201-206.

Google Scholar, Crossref, Indexed at

3. Liu, Jianzhao, Yanan Yue, Dali Han and Xiao Wang, et al. "A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation." Nat Chem Biol 10 (2014): 93-95.

Google Scholar, Crossref, Indexed at

4. Sun, Lei, Furqan M. Fazal, Pan Li and James P. Broughton, et al. "RNA structure maps across mammalian cellular compartments." Nat Struct Mol Biol 26 (2019): 322-330.

Google Scholar, Crossref, Indexed at

5. Gimple, Ryan C., Kailin Yang, Matthew E. Halbert and Sameer Agnihotri, et al. "Brain cancer stem cells: Resilience through adaptive plasticity and hierarchical heterogeneity." Nat Rev Cancer 22 (2022): 497-514.

Google Scholar, Crossref, Indexed at